D Habart

Summary

Affiliation: Institute of Hematology and Blood Transfusion
Country: Czech Republic

Publications

  1. ncbi [Molecular diagnosis of haemophilia A in clinical practice]
    D Habart
    Ostav hematologie a krevnĂ­ transfuze, Praha
    Cas Lek Cesk 144:795-800. 2005
  2. ncbi Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions
    D Habart
    Institute of Hematology and Blood Transfusion, Charles University, Prague, Czech Republic
    J Thromb Haemost 1:773-81. 2003
  3. ncbi [Molecular study of type 2 von Willebrand disease]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 142:373-6. 2003
  4. ncbi Simultaneous and semi-automated evaluation of three variable tandem repeats within von Willebrand factor gene by capillary electrophoresis with multicolour fluorescent detection
    David Habart
    Institute of Haematology and Blood Transfusion, Prague, Czech Republic
    Acta Haematol 110:41-2. 2003
  5. ncbi Laboratory tests for precise classification and genetic analysis of von Willebrand disease
    D Habart
    Institute of Haematology and Blood Transfusion, U Nemocnice 1, Prague 2, Czech Republic
    Sb Lek 104:237-45. 2003
  6. ncbi [Evaluation of DHPLC analysis for mutation detection in haemophilia A]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:484-7. 2006
  7. ncbi [Molecular pathogenesis of haemophilia A]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 144:727-32. 2005
  8. ncbi [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:104-11. 2006
  9. ncbi [Genetic databases. Though we were not the first ones, at least let us not to be the last]
    R Brdicka
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:897-900. 2006
  10. doi Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
    Giancarlo Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:3531-9. 2008

Collaborators

Detail Information

Publications14

  1. ncbi [Molecular diagnosis of haemophilia A in clinical practice]
    D Habart
    Ostav hematologie a krevnĂ­ transfuze, Praha
    Cas Lek Cesk 144:795-800. 2005
    ..Research is ongoing to establish less invasive prenatal testing and to move the testing to pre-gravid period...
  2. ncbi Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions
    D Habart
    Institute of Hematology and Blood Transfusion, Charles University, Prague, Czech Republic
    J Thromb Haemost 1:773-81. 2003
    ..Molecular modeling suggested mechanisms by which substitutions at residues 382 and 569, located outside the proposed FIXa-binding region, may influence FVIII/FIXa interaction. His2155 was predicted to participate in FVIII/VFW binding...
  3. ncbi [Molecular study of type 2 von Willebrand disease]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 142:373-6. 2003
    ..We attempted to characterise the phenotype and the genotype in the first five families in Czech Republic affected by this heterogeneous disorder...
  4. ncbi Simultaneous and semi-automated evaluation of three variable tandem repeats within von Willebrand factor gene by capillary electrophoresis with multicolour fluorescent detection
    David Habart
    Institute of Haematology and Blood Transfusion, Prague, Czech Republic
    Acta Haematol 110:41-2. 2003
  5. ncbi Laboratory tests for precise classification and genetic analysis of von Willebrand disease
    D Habart
    Institute of Haematology and Blood Transfusion, U Nemocnice 1, Prague 2, Czech Republic
    Sb Lek 104:237-45. 2003
    ..The purpose of this report is to inform about discriminatory and genetic tests recently made available at the Institute of Haematology and Blood transfusion...
  6. ncbi [Evaluation of DHPLC analysis for mutation detection in haemophilia A]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:484-7. 2006
    ..In order to speed up genotyping in haemophilia A families in the Czech Republic we evaluated DHPLC-based screening technique...
  7. ncbi [Molecular pathogenesis of haemophilia A]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 144:727-32. 2005
    ..The knowledge has been utilised in current diagnostic practice and developement of future therapeutic strategies...
  8. ncbi [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors]
    D Habart
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:104-11. 2006
    ..Ongoing studies in vitro and in vivo are trying to improve the effectiveness. Engineered molecules of factors VIII and IX already tested in vitro and in vivo, on animal models may in future improve both classical and gene therapies...
  9. ncbi [Genetic databases. Though we were not the first ones, at least let us not to be the last]
    R Brdicka
    Ustav hematologie a krevni transfuze, Praha
    Cas Lek Cesk 145:897-900. 2006
    ..European laws including the Czech Republic seem to be much less progressive. General rules for data storage, and gene banking are still missing in the Czech Republic...
  10. doi Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
    Giancarlo Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:3531-9. 2008
    ..The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD...
  11. ncbi Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)
    Anne Goodeve
    The Academic Unit of Haematology, University of Sheffield, United Kingdom
    Blood 109:112-21. 2007
    ..About one third of the type 1 VWD cases recruited could be reconsidered as type 2. The remaining group could be considered "true" type 1 VWD, although mutations were found in only 55%...
  12. ncbi Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination
    Ilona Hromadnikova
    2nd Department of Paediatrics, 2nd Medical Faculty, Charles University, University Hospital Motol, V Uvalu 84, 150 18 Prague 5, Czech Republic
    Prenat Diagn 23:235-8. 2003
    ..We determined fetal sex in pregnancies referred for invasive prenatal diagnosis procedures by analysis of DNA in maternal plasma...
  13. ncbi Recombinant coagulation factor VIIa in the management of bleeding in patients with von Willebrand disease type 2A
    Miloslava Matyskova
    Transfus Apher Sci 31:75-7. 2004
  14. pmc Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)
    Sandra L Haberichter
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, USA
    Blood 111:4979-85. 2008
    ..The systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 1 VWD patients may identify patients with a reduced VWF survival phenotype...